LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN) Commits US$50 Billion For US Expansion By 2030
AstraZeneca (LSE:AZN) recently announced plans to invest $50 billion in the U.S. by 2030, including the development of a major manufacturing facility in Virginia. Despite this significant announcement and other positive developments such as the EU approval of IMFINZI for bladder cancer, AstraZeneca's share price remained flat over the last quarter, reflecting broader market trends. The S&P 500 reached record highs, buoyed by trade deal optimism and solid earnings reports. These positive...